Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its pipeline centers on ORKA-001 and ORKA-002, with a third program, ORKA-003, aimed at an undisclosed pathway for inflammatory disease applications.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage antibody program targeting IL-23p19 for psoriasis.
Clinical-stage antibody program targeting IL-17A/F for psoriasis, HS, and related I&I diseases.
Earlier-stage undisclosed pathway program for inflammatory dermatology and I&I expansion.
Exclusive worldwide rights to develop and commercialize licensed antibody programs.
Asiakkaat
Oruka does not yet sell commercial products; its near-term counterparties are clinical trial sites, contract research organizations, contract manufacturers, and other development partners that support its pipeline. If approved, its eventual customers would be physicians, hospitals, and specialty pharmacies serving patients with psoriasis, hidradenitis suppurativa, psoriatic arthritis, and related inflammatory diseases.
CROs, investigators, labs, and CMOs that execute studies and supply drug material.
Physicians treating psoriasis, HS, PsA, and other inflammatory conditions if products are approved.
Hospitals, specialty pharmacies, and distributors that would handle commercial access.
Strategia
Oruka’s strategy is to focus on a small number of differentiated antibody programs in inflammatory dermatology, using validated biology and half-life extension to improve dosing convenience. It seeks to advance ORKA-001 and ORKA-002 through clinical development while preserving optionality for future commercialization or strategic collaboration.
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
Longer dosing intervals can improve adoption versus existing biologics.
A flexible go-to-market model can maximize value if programs succeed.
Maantiede
Oruka is headquartered in Menlo Park, California and operates as a U.S.-based development company. Its programs are intended for the United States and other key markets, and its clinical and regulatory work can extend into foreign jurisdictions through global trial and licensing activities.
Riskit
Oruka is a clinical-stage company with no approved products, so its value depends on successful trial outcomes, regulatory clearance, and eventual manufacturing scale-up. It also relies on third parties for research, manufacturing, and supply, while its licensed programs carry milestone and royalty obligations to Paragon.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Pipeline value depends on positive efficacy and safety data in psoriasis and related indications.
Kohdistuu - Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
As a pre-revenue biotech, continued operations depend on external capital.
Kohdistuu: Operating runway and future development spend
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even successful trials may not translate into approval or favorable labeling.
Kohdistuu: U.S. and foreign regulatory filings
- Third-party manufacturing and supply dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company does not own manufacturing facilities and relies on CMOs and suppliers.
Kohdistuu - IP and license dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Core programs are licensed from Paragon and carry milestone and royalty obligations.
Kohdistuu: ORKA-001 and ORKA-002 license agreements
Kirjanpito
Harkinnanvaraiset erätMilestone payments and external service costs are expensed as incurred, affecting period-to-period comparability.
Vaikutus: Clinical milestone timing can create volatility in reported operating expenses.
ORKA-001 and ORKA-002 carry future milestone and royalty payments to Paragon.
Vaikutus: These obligations affect accrued liabilities and future cash outflows.
The company’s current structure resulted from a reverse merger and recapitalization.
Vaikutus: Purchase accounting, equity presentation, and transaction costs can materially affect reported results.
Operating leases for Menlo Park and Waltham create fixed contractual obligations.
Vaikutus: Lease liabilities and right-of-use assets affect the balance sheet and cash flow presentation.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
MoonLake Immunotherapeutics
MLTX · Pharmaceutical Preparations
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F…
Kiniksa Pharmaceuticals International, plc
KNSA · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical…
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Arcutis Biotherapeutics, Inc.
ARQT · Pharmaceutical Preparations
Arcutis Biotherapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on dermatology.
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Päivitetty: 24.9.2026